Patients with previously treated metastatic pancreatic cancer survived a median of 13.2 months on the oral drug daraxonrasib, compared with 6.6 months on standard chemotherapy, according to results from a 500-patient phase 3 trial called RASolute 302. The findings, published in the New England Journal of Medicine, represent the first time a targeted pill has doubled overall survival in this patient population. The FDA has already acted on the data, permitting expanded access to the investigational drug and granting it both Breakthrough Therapy and Orphan Drug designations.
What the RASolute 302 trial showed
RASolute 302 is a global, randomized, open-label study that enrolled approximately 500 patients whose metastatic pancreatic ductal adenocarcinoma had progressed after at least one prior line of treatment. Patients were assigned either to daraxonrasib, also known as RMC-6236, or to investigator-chosen standard-of-care chemotherapy. The trial is registered on ClinicalTrials.gov under identifier NCT06625320.
The primary endpoint was overall survival, and the drug cleared that bar decisively. A median of 13.2 months versus 6.6 months translates to patients living roughly twice as long on the experimental pill as they did on chemotherapy their doctors selected from existing options. For a cancer that kills most people within a year of an advanced diagnosis, that gap carries real weight for the roughly 64,000 Americans diagnosed with pancreatic cancer each year and for the oncologists who have had few effective second-line choices.
The trial targeted tumors harboring RAS mutations, which drive the vast majority of pancreatic cancers. Daraxonrasib works by inhibiting multiple RAS variants rather than a single mutation, a strategy that could explain its broad effect across the enrolled population. The study’s open-label design means neither patients nor physicians were blinded to treatment assignment, a common approach in oncology trials where the side-effect profiles of oral targeted therapy and intravenous chemotherapy differ too much for effective blinding.
Secondary endpoints included progression-free survival and objective response rate. Patients receiving daraxonrasib experienced longer periods before their disease worsened and higher rates of measurable tumor shrinkage than those on chemotherapy. While exact numbers for each subgroup remain limited in public summaries, the direction of benefit was consistent across prespecified analyses, including age, performance status, and number of prior therapies.
Investigators also reported that dose interruptions and reductions were manageable, allowing most patients to remain on therapy long enough to see clinical benefit. That contrasts with some cytotoxic regimens, where cumulative toxicity often forces early discontinuation. Still, the open-label nature of the trial and its focus on a molecularly selected population mean that real-world effectiveness could differ once the drug is used outside specialized centers.
What the FDA has done so far
Before the trial results were even published, the FDA permitted an expanded-access treatment protocol for daraxonrasib, declaring it “safe to proceed.” Expanded access allows patients who cannot enroll in a clinical trial to receive an investigational drug while it is still under regulatory review. The agency also referenced the drug’s prior Breakthrough Therapy designation, which is reserved for therapies that show substantial improvement over existing treatments, and its Orphan Drug designation, which applies to drugs targeting diseases affecting fewer than 200,000 Americans.
Agency documents noted the sponsor’s stated intent to file a new-drug application. If the company follows the timeline that Breakthrough Therapy designation is designed to accelerate, a formal approval decision could arrive well before the standard review clock would otherwise run out. The FDA has used this pathway to shorten review periods for other oncology drugs by several months, though each case depends on the completeness of the submission and any additional data requests.
Patients or caregivers seeking information about the expanded-access program can reach the agency through its online contact portal. The program’s existence signals that regulators view the benefit-risk profile favorably enough to allow use outside a controlled trial setting, a step the FDA does not take lightly. Physicians who wish to participate typically must coordinate with both the sponsor and the agency, ensuring that safety monitoring and reporting requirements are in place.
What remains uncertain
Several questions sit between the trial results and routine clinical use. The published data report median overall survival, but full subgroup analyses, including how patients with specific RAS mutation subtypes such as KRAS G12D or G12V responded, have not been released in detail beyond summary statistics. Those breakdowns matter because oncologists will want to know whether the survival benefit holds evenly across mutation types or concentrates in a subset.
Tolerability data also remain incomplete in the public record. The NEJM publication covers safety endpoints including grade 3 or higher adverse events and treatment discontinuation rates, but direct statements from investigators or patients about day-to-day side effects have not appeared in the FDA announcement or the ClinicalTrials.gov registry entry. For a drug taken as a daily pill rather than administered intravenously, quality-of-life measures and long-term adherence patterns will shape how aggressively oncologists prescribe it.
Long-term follow-up beyond the primary analysis cutoff has not been reported. Median survival tells the story at the halfway mark of the patient population, but tail-of-the-curve data, showing what fraction of patients are alive at 18 or 24 months, will determine whether daraxonrasib produces durable responses or whether its benefit narrows over time. Real-world outcomes from the expanded-access cohort, including discontinuation rates and reasons for stopping treatment, are not yet captured in any public registry or filing.
Cost and access are additional unknowns. As with many targeted oncology agents, pricing will influence whether insurers place restrictions on use or require failure of multiple prior regimens. Community oncology practices may also face logistical hurdles in molecular testing to confirm RAS-mutant status in all eligible patients, particularly when tissue samples are scarce or archival.
How to read the evidence
The strongest evidence here comes from two primary sources. The peer-reviewed trial report provides detailed survival curves, safety tables, and statistical methods, allowing independent clinicians and researchers to scrutinize the magnitude and consistency of benefit. The FDA’s regulatory communication confirms that the agency has reviewed enough data to justify expanded access and special designations, but it offers less granularity on subgroup results and long-term outcomes.
Readers should distinguish between median improvements and absolute survival times. Doubling median overall survival from 6.6 to 13.2 months is clinically meaningful, yet it still reflects a disease with a high mortality rate. For patients and families, the value of those additional months depends heavily on symptom control, functional status, and the burden of side effects-dimensions that early publications only partially capture.
It is also important to recognize the limitations of an open-label design. Knowledge of treatment assignment can influence both patient-reported outcomes and physician decisions about imaging frequency, dose modifications, and switching therapies. While overall survival is less susceptible to such bias than endpoints like progression-free survival, subtle differences in supportive care or follow-up could still affect results.
For now, daraxonrasib looks like a rare advance in a field where progress has been incremental at best. The RASolute 302 data suggest that targeting a key oncogenic pathway across multiple mutations can extend life meaningfully for patients whose options have been limited to toxic chemotherapies with modest benefit. At the same time, unanswered questions about durability, tolerability in broader practice, and equitable access argue for cautious optimism rather than premature celebration.
Clinicians will be watching closely as longer-term follow-up, real-world expanded-access experience, and regulatory review unfold. Patients considering the drug should discuss with their oncologists how the trial population compares with their own situation, what is known about side effects, and whether participation in ongoing studies or expanded-access programs is feasible. The emerging story of daraxonrasib underscores both how far pancreatic cancer treatment has come-and how far it still has to go.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
